Phase 2 CARAT trial fails to meet primary endpoint
Mar 18, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the arteries of patients who had recently had a heart attack did not reduce the volume of fatty deposits, or plaque, in the arteries,...
Phase 2 study finds replacing aspirin with anticoagulant appears to be safe
Mar 18, 2017
Patients with acute coronary syndrome who were treated with the blood-thinning drug rivaroxaban in addition to an antiplatelet medication (clopidogrel or ticagrelor) experienced no increase in bleeding complications compared with patients who...
Major trial meets non-inferiority endpoint for all-cause death and disabling stroke at two years
Mar 17, 2017
Two-year data reveal no difference in the combined rate of stroke and death from any cause when comparing the use of self-expanding transcatheter aortic valve replacement (TAVR) with standard open-heart surgery in intermediate risk patients with...
Drug improves cardiovascular outcomes in high-risk patients with higher LDL cholesterol at baseline; no benefit seen in patients with lower LDL
Mar 17, 2017
In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of effective statin therapy, had widely varying effects on LDL cholesterol levels and had no benefit on cardiovascular events ...
First outcomes trial of this PCSK9 inhibitor shows consistent benefit across patient subgroups, confirms marked drops in LDL cholesterol
Mar 17, 2017
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of cardiovascular events in patients with...